Bladder Cancer clinical trials in Vermont

7 actively recruiting bladder cancer trials at 5 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05987241

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07061964

Sites in Vermont:

Dartmouth Cancer Center - North — Saint Johnsbury, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06770582

Sites in Vermont:

Central Vermont Medical Center/National Life Cancer Treatment — Berlin Corners, Vermont
University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting Federal

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary sympt…

Sponsor: White River Junction Veterans Affairs Medical Center

NCT ID: NCT05796375

Sites in Vermont:

White River Junction Veterans Healthcare System — White River Junction, Vermont

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cel…

Sponsor: Eli Lilly and Company

NCT ID: NCT05614739

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont

View on ClinicalTrials.gov →

Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska

NCT ID: NCT02012699

Sites in Vermont:

Rutland Regional Medical Center — Rutland, Vermont

View on ClinicalTrials.gov →

Recruiting Industry

Longitudinal Bladder Cancer Study for Tumour Recurrence

Surveillance for recurrence of urothelial carcinoma (UC) requires frequent cystoscopy, which is invasive, expensive and time-consuming. An accurate urinary biomarker has the potential to reduce the number of cystoscopies required during po…

Sponsor: Pacific Edge Limited

NCT ID: NCT05080998

Sites in Vermont:

White River Junction Veterans Affair Medical Center — White River Junction, Vermont

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20